Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Discovery and Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancer

Friday, November 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery and preclinical characterization of ALG-093940, a new small molecule PD-L1 inhibitor. This compound is noted for its potent activity and oral bioavailability, which may enhance its application in cancer therapy. The findings suggest promising avenues for further development in clinical settings.
Price reaction · baseline $10.15 (2024-11-08T20:58:00.000Z) · hit during market hours · clean, no other ALGS news in the window
day 0 close · peak
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of a new PD-L1 inhibitor shows potential for cancer treatment.
  • Oral bioavailability may improve patient compliance and treatment outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-093940?

ALG-093940 is a newly discovered small molecule PD-L1 inhibitor for cancer treatment.

How does ALG-093940 work?

It inhibits PD-L1, potentially enhancing the immune response against cancer cells.

What are the benefits of ALG-093940?

Its oral bioavailability may improve patient compliance and treatment effectiveness.

What stage is ALG-093940 currently in?

It is in the preclinical characterization phase, with further studies anticipated.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-093940 PD-L1 cancer treatment oral bioavailability preclinical study
Last updated: Nov 8, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →